Guest guest Posted December 30, 2010 Report Share Posted December 30, 2010 http://www.medscape.org/viewarticle/734033 E. Dearden, MD, FRCP Includes discussion of safety and efficacy data on CAL101 and the btk inhibitor - also active in other indolent lymphomas Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.